The experimental and clinical use of polymyxin, chloromycetin, and aureomycin.
Polymyxin is an effective antibiotic for the treatment of severe infections produced by Ps. aeruginosa, H. pertussis, H. influenzae, E. coli, and A. aerogenes. Its toxicity to date precludes its general use in infections susceptible to its therapeutic effects. Chloromycetin has been demonstrated to be an effective antibiotic agent for the treatment of rickettsial diseases and typhoid fever. It will undoubtedly prove effective in the treatment of other infections produced by certain Gram-negative micro-organisms and viral agents. Aureomycin has been shown to be an active antibiotic agent against rickettsial diseases, primary atypical pneumonia, acute brucellosis, pneumococcal, streptococcal, and staphylococcal infections, urinary tract infections produced by E. coli, A. aerogenes and Strept. fecalis, certain types of infections of the eye, and in subacute bacterial endocarditis when the infecting agent is Strept. fecalis. Its clinical use in forms of extrapulmonary tuberculosis is in a completely experimental stage. It is not recommended in typhoid fever or in infections due to Ps. aeruginosa or P. vulgaris, and it seems to be ineffective in whooping cough. To date, neither chloromycetin nor aureomycin has shown significant signs of systemic toxicity.
D000900:Anti-Bacterial Agents; D002006:Brucellosis; D002701:Chloramphenicol; D002751:Chlortetracycline; D004926:Escherichia coli; D011113:Polymyxins; D012282:Rickettsia Infections; D014435:Typhoid Fever; D014917:Whooping Cough
D000900:Anti-Bacterial Agents; D011113:Polymyxins; D002701:Chloramphenicol; D002751:Chlortetracycline
AUREOMYCIN; CHLOROMYCETIN; POLYMYXIN